{"classes":[{"categories":[{"measurements":[{"comment":"The upper 95% CI was not estimated due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"4.14","upperLimit":"NA","value":"5.72"},{"comment":"The upper 95% CI was not estimated due to insufficient number of participants with events","groupId":"OG001","lowerLimit":"4.80","upperLimit":"NA","value":"6.93"},{"comment":"The upper 95% CI was not estimated due to insufficient number of participants with events","groupId":"OG002","lowerLimit":"0.49","upperLimit":"NA","value":"6.08"},{"comment":"The median and 95% CIs were not estimated due to insufficient number of participants with events","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"The median and upper 95% CI were not estimated due to insufficient number of participants with events","groupId":"OG004","lowerLimit":"3.55","upperLimit":"NA","value":"NA"},{"comment":"The median and upper 95% CI were not estimated due to insufficient number of participants with events","groupId":"OG005","lowerLimit":"1.64","upperLimit":"NA","value":"NA"},{"comment":"The upper 95% CI was not estimated due to insufficient number of participants with events","groupId":"OG006","lowerLimit":"5.72","upperLimit":"NA","value":"6.93"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"81"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as time from Cycle 1 Day 1 to the date of death (or date last known to be alive). OS was analyzed using the K-M method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Metastatic colorectal cancer (CRC) defined as histologically and/or cytologically confirmed CRC, and must have received at least 1 prior regimen for advanced/metastatic disease.","id":"OG000","title":"Colorectal Cancer"},{"description":"High grade serous ovarian cancer (HGSOC) defined as histologically confirmed high grade serous ovarian, fallopian tube or primary peritoneal cancer who were recurrent platinum intolerant, or with platinum resistant disease defined as radiological evidence of disease progression within 6 months of the last receipt of platinum based chemotherapy.","id":"OG001","title":"High Grade Serous Ovarian Cancer"},{"description":"Advanced non small cell lung cancer (NSCLC) defined as locally advanced and recurrent or metastatic, histologically confirmed NSCLC, and must have received at least 1 prior regimen for advanced/metastatic disease.","id":"OG002","title":"Non Small Cell Lung Cancer"},{"description":"Metastatic castration resistant prostate cancer (mCRPC) defined as histologically or cytologically confirmed adenocarcinoma of the prostate that has progressed after androgen deprivation therapy.","id":"OG003","title":"Metastatic Castration Resistant Prostate Cancer"},{"description":"Histologically confirmed HNSCC from any primary site; locally advanced disease (ie, persistent or progressive disease following curative intent radiation, and not a candidate for surgical salvage due to incurability or morbidity), or metastatic disease.","id":"OG004","title":"Head and Neck Squamous Cell Carcinoma"},{"description":"Any locally advanced or metastatic, histologically or cytologically proven solid tumor or NHL, that had relapsed after or progressing despite conventional treatment for which no conventional therapy was considered appropriate by the investigator or had been declined by the subject.","id":"OG005","title":"Other Tumor Type"},{"description":"All subjects included in the Response Evaluable Population","id":"OG006","title":"Overall"}],"paramType":"MEDIAN","populationDescription":"The Response Evaluable Population (REP) included all subjects who satisfy the following conditions:\n\n1. Measurable disease and assessment at baseline\n2. Received at least 75% of 1 cycle of study medication, based on dosing information\n3. At least 1 post baseline disease assessment OR discontinued treatment due to AE or disease progression or death Note: The median OS was not estimated in the mCRPC, HNSCC, or \"Other\" tumor type subgroups due to insufficient number of participants with events.","reportingStatus":"POSTED","timeFrame":"Follow-up assessments were made every 16 weeks for subjects who had not progressed and had not initiated new anticancer therapy.","title":"Overall Survival (OS)","type":"PRIMARY","unitOfMeasure":"months"}